Latanoprost ophthalmic Pregnancy Warnings
AU, US: This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.
UK: Use should be avoided.
AU TGA pregnancy category: B3
US FDA pregnancy category: C
Animal studies have revealed no malformations or structural variations. There are no adequate studies in pregnant women.
AU TGA pregnancy category B3: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans.
US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
See references
